Details

Autor(en) / Beteiligte

• Baeten, Jared M
• Donnell, Deborah
• Ndase, Patrick
• Mugo, Nelly R
• Campbell, James D
• Wangisi, Jonathan
• Tappero, Jordan W
• Bukusi, Elizabeth A
• Cohen, Craig R
• Katabira, Elly
• Ronald, Allan
• Tumwesigye, Elioda
• Were, Edwin
• Fife, Kenneth H
• Kiarie, James
• Farquhar, Carey
• John-Stewart, Grace
• Kakia, Aloysious
• Odoyo, Josephine
• Mucunguzi, Akasiima
• Nakku-Joloba, Edith
• Twesigye, Rogers
• Ngure, Kenneth
• Apaka, Cosmas
• Tamooh, Harrison
• Gabona, Fridah
• Mujugira, Andrew
• Panteleeff, Dana
• Thomas, Katherine K
• Kidoguchi, Lara
• Krows, Meighan
• Revall, Jennifer
• Morrison, Susan
• Haugen, Harald
• Emmanuel-Ogier, Mira
• Ondrejcek, Lisa
• Coombs, Robert W
• Frenkel, Lisa
• Hendrix, Craig
• Bumpus, Namandjé N
• Bangsberg, David
• Haberer, Jessica E
• Stevens, Wendy S
• Lingappa, Jairam R
• Celum, Connie

Titel

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

Ist Teil von

• The New England journal of medicine, 2012-08, Vol.367 (5), p.399-410

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• In this study of 4758 HIV-1–serodiscordant heterosexual couples in Kenya and Uganda, daily antiretroviral prophylaxis (with tenofovir or emtricitabine–tenofovir) in the HIV-1–negative partner significantly decreased the risk of HIV infection. The use of antiretroviral medications for the prevention of HIV type 1 (HIV-1) transmission is a promising strategy for reducing the spread of HIV-1. 1 – 4 Antiretroviral treatment for persons infected with HIV-1 provides important clinical benefits and substantially reduces infectiousness. 5 – 7 Antiretroviral prophylaxis is a potential HIV-1–prevention strategy for those not yet infected with HIV-1, administered either as postexposure prophylaxis after high-risk occupational or nonoccupational exposure or as preexposure prophylaxis in those with ongoing HIV-1 exposure. 8 , 9 The rationale for antiretroviral prophylaxis in persons with ongoing exposure is based on its efficacy in infants exposed to HIV-1 during birth and . . .